HCW Biologics Inc
Company Profile
Business description
HCW Biologics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel immunotherapies to lengthen the health span by disrupting the link between chronic, low-grade inflammation and age-related diseases. The company has developed TOBI discovery platform, or Tissue factor-based fusion discovery platform, for the design of category-defining immunotherapeutic drugs. It has selected two molecules as its product candidate; HCW9218 and HCW9302. HCW9218 is a bifunctional immunotherapeutic designed with the capabilities to neutralize transforming growth and stimulate immune cells. HCW9302 is designed to activate and expand regulatory T cells, which deactivate inflammasomes.
Contact
2929 N Commerce Parkway
MiramarFL33025
USAT: +1 954 842-2024
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2025
Employees
36
Stocks News & Analysis
stocks
Netflix: A business that’s nearly flawless
stocks
Trump’s US dollar assault is fuelling CBA’s rise
stocks
Insignia Financial: Revised deal still attractive
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 8,979.40 | 22.00 | -0.24% |
CAC 40 | 7,850.43 | 106.02 | 1.37% |
DAX 40 | 24,240.82 | 198.92 | 0.83% |
Dow JONES (US) | 45,010.29 | 507.85 | 1.14% |
FTSE 100 | 9,061.49 | 37.68 | 0.42% |
HKSE | 25,621.79 | 83.72 | 0.33% |
NASDAQ | 21,020.02 | 127.33 | 0.61% |
Nikkei 225 | 41,881.24 | 709.92 | 1.72% |
NZX 50 Index | 12,805.13 | 11.07 | 0.09% |
S&P 500 | 6,358.91 | 49.29 | 0.78% |
S&P/ASX 200 | 8,709.60 | 27.60 | -0.32% |
SSE Composite Index | 3,593.84 | 11.54 | 0.32% |